New data from The Harris Poll reveals that two things have been top in the minds of leading oncologists: ASCO 2022 and health equity. The conference, held in the first week of June, is a flagship meeting for the field, and was discussed by 61% of oncologists studied from March to the end of June. Health Equity was discussed by 15%. Another major topic was ongoing clinical trials.
According to Beth Snyder Bulik, “Among the specific clinical trials and studies talked about, the AstraZeneca and Daiichi Sankyo’s Destiny study presented on Enhertu (trastuzumab deruxtecan) in previously treated HER2-low advanced breast cancer led the way with 19% talking about it on Twitter. Tied for the second-most discussed study at 11% were GSK’s PD-1 blocker dostarlimab-gxly (Jemperli) rectal cancer trial and the Cosmic-021 for cabozantinib–atezolizumab (Exelixis’ Cabometyx and Roche’s Tecentriq) to treat urothelial carcinoma.”
To read more, click here.
(Source: Endpoints News, July 1st, 2022)